
Menarini Showcases ORSERDU® Advances at SABCS 2024 for ER+, HER2- mBC
Menarini Presents Data at SABCS 2024 Showcasing ORSERDU®’s Potential in ER+/HER2- Metastatic Breast Cancer The Menarini Group and its subsidiary, Stemline Therapeutics, are set to unveil new and expanded findings…













